## Jane Pei-Chen Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/278489/publications.pdf

Version: 2024-02-01

51 papers 1,422 citations

393982 19 h-index 36 g-index

51 all docs

51 docs citations

51 times ranked

1818 citing authors

#	Article	IF	CITATIONS
1	Does the â€ <sup>-</sup> hikikomori' syndrome of social withdrawal exist outside Japan? A preliminary international investigation. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 1061-1075.	1.6	188
2	Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial. Biological Psychiatry, 2014, 76, 559-566.	0.7	173
3	Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology, 2018, 43, 534-545.	2.8	149
4	Maternal parenting styles and mother–child relationship among adolescents with and without persistent attention-deficit/hyperactivity disorder. Research in Developmental Disabilities, 2013, 34, 1581-1594.	1.2	96
5	Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 129, 1-12.	1.0	74
6	Cortisol, inflammatory biomarkers and neurotrophins in children and adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. Brain, Behavior, and Immunity, 2020, 88, 105-113.	2.0	56
7	High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels. Translational Psychiatry, 2019, 9, 303.	2.4	52
8	Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain, Behavior, and Immunity, 2019, 80, 512-518.	2.0	44
9	Introducing the concept of modern depression in Japan; an international case vignette survey. Journal of Affective Disorders, 2011, 135, 66-76.	2.0	40
10	Melatonergic agonist regulates circadian clock genes and peripheral inflammatory and neuroplasticity markers in patients with depression and anxiety. Brain, Behavior, and Immunity, 2020, 85, 142-151.	2.0	38
11	Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder – Results from a randomized controlled trial. Brain, Behavior, and Immunity, 2020, 85, 14-20.	2.0	34
12	Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents. Clinical Psychopharmacology and Neuroscience, 2020, 18, 469-483.	0.9	33
13	Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 273-278.	2.5	30
14	Melatonergic agents in the prevention of delirium: A network meta-analysis of randomized controlled trials. Sleep Medicine Reviews, 2020, 50, 101235.	3.8	29
15	Cortisol and inflammatory biomarker levels in youths with attention deficit hyperactivity disorder (ADHD): evidence from a systematic review with meta-analysis. Translational Psychiatry, 2021, 11, 430.	2.4	29
16	Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia. Biological Psychology, 2010, 83, 79-83.	1.1	28
17	Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 227-233.	2.5	25
18	Omega-3 fatty acids in the psychological and physiological resilience against COVID-19. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 161, 102177.	1.0	25

#	Article	IF	CITATIONS
19	Polyunsaturated fatty acids (PUFAs) levels in patients with cardiovascular diseases (CVDs) with and without depression. Brain, Behavior, and Immunity, 2015, 44, 28-31.	2.0	24
20	Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women. Brain, Behavior, and Immunity, 2020, 85, 29-34.	2.0	22
21	Mother-Child Relationship in Youths with Attention-Deficit Hyperactivity Disorder and their Siblings. Journal of Abnormal Child Psychology, 2017, 45, 871-882.	3.5	19
22	The Efficacy of Omega-3 Fatty Acids for Depressive Symptoms among Pregnant Women in Japan and Taiwan: A Randomized, Double-Blind, Placebo-Controlled Trial (SYNCHRO; NCT01948596). Psychotherapy and Psychosomatics, 2019, 88, 122-124.	4.0	18
23	Reliability and validity of three Chineseâ€version tasks of Mayer–Salovey–Caruso Emotional Intelligence Test. Journal of Clinical Nursing, 2010, 19, 2656-2658.	1.4	16
24	Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in Cardiovascular Diseases (CVDs) and Depression: The Missing Link?. Cardiovascular Psychiatry and Neurology, 2009, 2009, 1-6.	0.8	15
25	Delay Aversion, Temporal Processing, and N-3 Fatty Acids Intake in Children With Attention-Deficit/Hyperactivity Disorder (ADHD). Clinical Psychological Science, 2016, 4, 1094-1103.	2.4	15
26	Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. Nutritional Neuroscience, 2017, 20, 291-296.	1.5	14
27	Major depressive episodes during pregnancy and after childbirth: A prospective longitudinal study in Taiwan. Journal of the Formosan Medical Association, 2019, 118, 1551-1559.	0.8	13
28	Nutrition and immunology in mental health: Precision medicine and integrative approaches to address unmet clinical needs in psychiatric treatments. Brain, Behavior, and Immunity, 2020, 85, 1-3.	2.0	13
29	Paliperidone overdose in a patient with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 418.	2.5	12
30	Banl polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 136, 111-115.	1.0	12
31	A case of venlafaxine-induced bruxism alleviated by duloxetine substitution. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 307.	2.5	11
32	Maternal and Family Processes in Different Subgroups of Youth with Autism Spectrum Disorder. Journal of Abnormal Child Psychology, 2019, 47, 177-194.	3.5	11
33	Efficacy and acceptability of different interventions for acrophobia: A network meta-analysis of randomised controlled trials. Journal of Affective Disorders, 2021, 282, 786-794.	2.0	9
34	Depression-free after Interferon-α exposure indicates less incidence of depressive disorder: A longitudinal study in Taiwan. Brain, Behavior, and Immunity, 2020, 88, 125-131.	2.0	9
35	Serotonin-Norepinephrine Reuptake Inhibitor Treatment for Tinnitus and Depression. Journal of Clinical Psychopharmacology, 2012, 32, 729.	0.7	7
36	Genetic Variations of Ionotropic Glutamate Receptor Pathways on Interferon-α-induced Depression in Patients with Hepatitis C Viral Infection. Brain, Behavior, and Immunity, 2021, 93, 16-22.	2.0	6

#	Article	IF	Citations
37	Kawasaki disease in childhood and psychiatric disorders: A population-based case-control prospective study in Taiwan. Brain, Behavior, and Immunity, 2022, 100, 105-111.	2.0	6
38	Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole. Schizophrenia Research, 2011, 132, 97-98.	1.1	5
39	Differences between Japan and Taiwan in the treatment of pregnant women with depressive symptoms by omega-3 fatty acids: An open-label pilot study. Nutritional Neuroscience, 2019, 22, 63-71.	1.5	4
40	Somatic pain associated with initiation of interferon-alpha (IFN- $\hat{l}$ ±) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study. Brain, Behavior, & Immunity - Health, 2020, 2, 100035.	1.3	4
41	Personalised medicine in child and Adolescent Psychiatry: Focus on omega-3 polyunsaturated fatty acids and ADHD. Brain, Behavior, & Immunity - Health, 2021, 16, 100310.	1.3	4
42	A Case of Milnacipran-Related Sweating Alleviated by Duloxetine Substitution. Journal of Clinical Psychopharmacology, 2010, 30, 640-641.	0.7	3
43	Serotonin-Norepinephrine Reuptake Inhibitor–Associated Mixed Episode in an Adolescent With Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2014, 34, 525-526.	0.7	2
44	Challenges and opportunities for early career child mental health professionals during the COVID19 pandemic. Asian Journal of Psychiatry, 2020, 54, 102443.	0.9	2
45	Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) treatment for Isaacs syndrome with depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 739-740.	2.5	1
46	More fish-happier mom, smarter child?. Brain, Behavior, and Immunity, 2018, 73, 157-158.	2.0	1
47	Identification of Genetic Variations in the NAD-Related Pathways for Patients with Major Depressive Disorder: A Case-Control Study in Taiwan. Journal of Clinical Medicine, 2022, 11, 3622.	1.0	1
48	Atypical major depressive episode as initial presentation of intracranial germinoma in a male adolescent. Neuropsychiatric Disease and Treatment, 2016, Volume 13, 35-40.	1.0	0
49	Diet, Immune System, and Psychiatric Disorders. , 2021, , 401-415.		O
50	Omega-3 Polyunsaturated Fatty Acids (PUFAs) as the "Mind-Body Interface" in Cardiovascular Diseases and Depression., 2011,, 58-65.		0
51	Lipids and mental health. , 2022, , 51-73.		0